Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

Background Several tyrosine kinase inhibitors (TKIs) are available for treatment of patients
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Most patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1
tyrosine kinase inhibitors (TKIs) will achieve favorable responses. Moreover, TKI therapy …